Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.

Methods in molecular biology (Clifton, N.J.) - 1 Jan 2016

Wang Zhiqiang, Chen WenYong

Abstract excerpt

Tyrosine kinase inhibitors (TKIs) are the effective treatments for chronic myeloid leukemia (CML). However, clinical resistance to TKIs that leads to patient relapse remains a challenge. Acquisition of BCR-ABL mutations is crucial in the resistance but the underlying molecular mechanisms are poorly understood. Here we describe a cell culture model for CML acquired resistance in which blast crisis CML cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Blast Crisis
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 27581146
DOI: 10.1007/978-1-4939-4011-0_13
PMCID: PMC5010030

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.PMID 27581146Read ↗

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An UpdateSemantic proximity Read ↗

Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.Semantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a reviewSemantic proximity Read ↗

Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Resistance in chronic myeloid leukemia: definitions and novel therapeutic agentsSemantic proximity Read ↗

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.Semantic proximity Read ↗

Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemiaSemantic proximity Read ↗

BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.Semantic proximity Read ↗

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapiesSemantic proximity Read ↗

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.